Some like it hot

Despite signs the biotech rally is getting "toppy," market watchers ranging from buysiders to bankers to technical analysts think it can continue into this quarter. They say the market still has momentum and investors still have an appetite for risk.

Buysiders expect micro- and small caps could benefit the most, as many think valuations for large- and mid-cap biotechs have peaked...